240 related articles for article (PubMed ID: 37742785)
1. Ferroptosis in Parkinson's disease: Molecular mechanisms and therapeutic potential.
Ding XS; Gao L; Han Z; Eleuteri S; Shi W; Shen Y; Song ZY; Su M; Yang Q; Qu Y; Simon DK; Wang XL; Wang B
Ageing Res Rev; 2023 Nov; 91():102077. PubMed ID: 37742785
[TBL] [Abstract][Full Text] [Related]
2. Ferroptosis and its potential role in the physiopathology of Parkinson's Disease.
Mahoney-Sánchez L; Bouchaoui H; Ayton S; Devos D; Duce JA; Devedjian JC
Prog Neurobiol; 2021 Jan; 196():101890. PubMed ID: 32726602
[TBL] [Abstract][Full Text] [Related]
3. Toxic Feedback Loop Involving Iron, Reactive Oxygen Species, α-Synuclein and Neuromelanin in Parkinson's Disease and Intervention with Turmeric.
Jansen van Rensburg Z; Abrahams S; Bardien S; Kenyon C
Mol Neurobiol; 2021 Nov; 58(11):5920-5936. PubMed ID: 34426907
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Insights on Ferroptosis in Parkinson's disease.
Thapa K; Khan H; Kanojia N; Singh TG; Kaur A; Kaur G
Eur J Pharmacol; 2022 Sep; 930():175133. PubMed ID: 35792170
[TBL] [Abstract][Full Text] [Related]
5. Myricetin mitigates motor disturbance and decreases neuronal ferroptosis in a rat model of Parkinson's disease.
Gu SC; Xie ZG; Gu MJ; Wang CD; Xu LM; Gao C; Yuan XL; Wu Y; Hu YQ; Cao Y; Ye Q
Sci Rep; 2024 Jul; 14(1):15107. PubMed ID: 38956066
[TBL] [Abstract][Full Text] [Related]
6. The role of oxidative stress in Parkinson's disease.
Dias V; Junn E; Mouradian MM
J Parkinsons Dis; 2013; 3(4):461-91. PubMed ID: 24252804
[TBL] [Abstract][Full Text] [Related]
7. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
Perfeito R; Cunha-Oliveira T; Rego AC
Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292
[TBL] [Abstract][Full Text] [Related]
8. Calpain activation and progression of inflammatory cycles in Parkinson's disease.
Gao A; McCoy HM; Zaman V; Shields DC; Banik NL; Haque A
Front Biosci (Landmark Ed); 2022 Jan; 27(1):20. PubMed ID: 35090325
[TBL] [Abstract][Full Text] [Related]
9. Interrogating Parkinson's disease associated redox targets: Potential application of CRISPR editing.
Artyukhova MA; Tyurina YY; Chu CT; Zharikova TM; Bayır H; Kagan VE; Timashev PS
Free Radic Biol Med; 2019 Nov; 144():279-292. PubMed ID: 31201850
[TBL] [Abstract][Full Text] [Related]
10. Ferroptosis, a newly characterized form of cell death in Parkinson's disease that is regulated by PKC.
Do Van B; Gouel F; Jonneaux A; Timmerman K; Gelé P; Pétrault M; Bastide M; Laloux C; Moreau C; Bordet R; Devos D; Devedjian JC
Neurobiol Dis; 2016 Oct; 94():169-78. PubMed ID: 27189756
[TBL] [Abstract][Full Text] [Related]
11. Mitochondrial iron dyshomeostasis and its potential as a therapeutic target for Parkinson's disease.
Xiao Z; Wang X; Pan X; Xie J; Xu H
Exp Neurol; 2024 Feb; 372():114614. PubMed ID: 38007207
[TBL] [Abstract][Full Text] [Related]
12. Ferroptosis and cell death mechanisms in Parkinson's disease.
Guiney SJ; Adlard PA; Bush AI; Finkelstein DI; Ayton S
Neurochem Int; 2017 Mar; 104():34-48. PubMed ID: 28082232
[TBL] [Abstract][Full Text] [Related]
13. Ferroptosis in Parkinson's disease: glia-neuron crosstalk.
Wang ZL; Yuan L; Li W; Li JY
Trends Mol Med; 2022 Apr; 28(4):258-269. PubMed ID: 35260343
[TBL] [Abstract][Full Text] [Related]
14. JWA binding to NCOA4 alleviates degeneration in dopaminergic neurons through suppression of ferritinophagy in Parkinson's disease.
Zhao X; Kang Z; Han R; Wang M; Wang Y; Sun X; Wang C; Zhou J; Cao L; Lu M
Redox Biol; 2024 Jul; 73():103190. PubMed ID: 38744191
[TBL] [Abstract][Full Text] [Related]
15. Interactions of dopamine, iron, and alpha-synuclein linked to dopaminergic neuron vulnerability in Parkinson's disease and Neurodegeneration with Brain Iron Accumulation disorders.
Wise RM; Wagener A; Fietzek UM; Klopstock T; Mosharov EV; Zucca FA; Sulzer D; Zecca L; Burbulla LF
Neurobiol Dis; 2022 Dec; 175():105920. PubMed ID: 36351559
[TBL] [Abstract][Full Text] [Related]
16. Pathogenesis of α-Synuclein in Parkinson's Disease: From a Neuron-Glia Crosstalk Perspective.
Yi S; Wang L; Wang H; Ho MS; Zhang S
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499080
[TBL] [Abstract][Full Text] [Related]
17. Converging roles of ion channels, calcium, metabolic stress, and activity pattern of Substantia nigra dopaminergic neurons in health and Parkinson's disease.
Duda J; Pötschke C; Liss B
J Neurochem; 2016 Oct; 139 Suppl 1(Suppl Suppl 1):156-178. PubMed ID: 26865375
[TBL] [Abstract][Full Text] [Related]
18. Research progress in the molecular mechanism of ferroptosis in Parkinson's disease and regulation by natural plant products.
Yang K; Zeng L; Zeng J; Deng Y; Wang S; Xu H; He Q; Yuan M; Luo Y; Ge A; Ge J
Ageing Res Rev; 2023 Nov; 91():102063. PubMed ID: 37673132
[TBL] [Abstract][Full Text] [Related]
19. Demonstration of brain region-specific neuronal vulnerability in human iPSC-based model of familial Parkinson's disease.
Brazdis RM; Alecu JE; Marsch D; Dahms A; Simmnacher K; Lörentz S; Brendler A; Schneider Y; Marxreiter F; Roybon L; Winner B; Xiang W; Prots I
Hum Mol Genet; 2020 May; 29(7):1180-1191. PubMed ID: 32160287
[TBL] [Abstract][Full Text] [Related]
20. Trib3 Is Elevated in Parkinson's Disease and Mediates Death in Parkinson's Disease Models.
Aimé P; Sun X; Zareen N; Rao A; Berman Z; Volpicelli-Daley L; Bernd P; Crary JF; Levy OA; Greene LA
J Neurosci; 2015 Jul; 35(30):10731-49. PubMed ID: 26224857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
